

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
28 August 2008 (28.08.2008)

PCT

(10) International Publication Number
WO 2008/103621 A1

(51) International Patent Classification:

C04B 35/453 (2006.01) **C04B 35/45** (2006.01)

(21) International Application Number:

PCT/US2008/054190

(22) International Filing Date:

16 February 2008 (16.02.2008)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/890,673 20 February 2007 (20.02.2007) US
60/890,666 20 February 2007 (20.02.2007) US

(71) Applicant (for all designated States except US): **MI-CROBAN PRODUCTS COMPANY** [US/US]; 11515 Vanstory Drive, Suite 125, Huntersville, NC 28078 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **CAMPBELL, Alvin, Lamar** [US/US]; Microban Products Company, 11515 Vanstory Drive, Suite 125, Huntersville, NC 28078 (US).

(74) Agent: **WESTON, Cliff, D.**; Microban Products Company, 11515 Vanstory Drive, Suite 125, Huntersville, NC 28078 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(54) Title: CERAMIC GLAZE HAVING ANTIMICROBIAL PROPERTY

(57) Abstract: An antimicrobial ceramic glazing composition contains one or more antimicrobial agents disposed therein. Methods for making and using the glazing composition are disclosed, as well as substrates having a fired antimicrobial glaze thereon. The antimicrobial agents comprise metallic oxides, with a subset of the disclosed combinations exhibiting synergistic effect in fired glazes.

WO 2008/103621 A1

CERAMIC GLAZE HAVING ANTIMICROBIAL PROPERTY

5

[0001] FIELD OF THE INVENTION

10 **[0002]** The present invention relates to the field of antimicrobial protection in a ceramic article or component thereof. More specifically, the present invention relates to a composition for imparting built-in and long lasting antimicrobial characteristics to ceramic products.

15 BACKGROUND OF THE INVENTION

[0003] An area of particular commercial interest in the art is ceramic articles and ceramic coatings. Ceramic coatings are commonly used in products that store, treat, or transport water and liquid waste. Ceramic toilets, urinals, bidets, bathroom basins (collectively known as sanitary
20 ware), flooring tiles and other bathroom fixtures are probably the most common example of such products.

[0004] When used to collect, contain and/or transport water, ceramic products often become stained by scum and films of biologic origin (e.g., bacteria, fungus, mold, mildew). To date, the primary method of removing
25 biological scum and film from these ceramic products has been to abrade the ceramic surface in the presence of a topical cleaning agent.

[0005] There is a need for a ceramic coating that has built-in protection against the growth and proliferation of microbes. However, existing technologies are somewhat limited in this regard. For example, the
30 high temperatures used in ceramic firing processes typically preclude the use of organic antimicrobial agents.

[0006] Conventional inorganic silver-based antibacterial compounds (e.g., zeolite, amorphous glass, sol-gel) generally are too expensive for commercial use. Moreover, incorporation of silver-based antimicrobial agents into ceramic glazes routinely presents issues of clouding, crazing, 5 discoloration, and other undesirable consequences to the glaze aesthetics.

[0007] Zinc oxide is known as having antimicrobial characteristics and has been used in the preparation of ceramic glazing compositions. However, known ceramic glazing compositions that rely solely upon zinc oxide as an antimicrobial agent have not shown antimicrobial efficacy 10 sufficient for control of microbial growth and proliferation on ceramic surfaces.

[0008] Accordingly, there is a need for a low-cost ceramic coating that offers persistent built-in antimicrobial protection.

15 DETAILED DESCRIPTION

[0009] As used herein, the terms "microbe" or "microbial" should be interpreted to refer to any of the microscopic organisms studied by microbiologists or found in the use environment of a ceramic article or ceramic-glazed article. Such organisms include, but are not limited to, 20 bacteria and fungi as well as other single-celled organisms such as mold, mildew and algae. Viral particles and other infectious agents are also included in the term microbe.

[0010] As well, "antimicrobial" and like terms should be interpreted as encompassing both microbe-killing as well as microbistatic activities. That 25 is, it herein is considered efficacious if an antimicrobial composition reduces the number of microbes on a substrate or if the composition retards the normal rate of microbial growth.

[0011] For ease of discussion, this description uses the terms microbes and antimicrobial to denote a broad spectrum activity (e.g. against 30 bacteria and fungi). When speaking of efficacy against a particular

microorganism or taxonomic rank, the more focused term will be used (e.g. antifungal to denote efficacy against fungal growth in particular).

[0012] Using the above example, it should be understood that efficacy against fungi does not in any way preclude the possibility that the same antimicrobial composition demonstrates efficacy against another class.

[0013] For example, discussion of the strong bacterial efficacy demonstrated by a disclosed embodiment should not be read to exclude the embodiment from also demonstrating antifungal activity. This method of presentation should not be interpreted as limiting the scope of the invention in any way.

[0014] A first embodiment is an antimicrobial ceramic glaze composition. A second embodiment disclosed herein is a method for making an antimicrobial ceramic glazing composition. The glaze composition comprises a plurality of conventional glaze ingredients and a combination of antimicrobial agents, as described more fully below.

[0015] The following brief discussion of ceramic coatings and in particular to ceramic glazing on the outer surfaces of ceramic products and of vitreous china or ceramic production is provided as an aid to the reader. This discussion is presented in the context of the production of bathroom fixtures. Those skilled in the art recognize that the production process of ceramic products may vary from that which is presented below, and that the ceramic glazing process disclosed herein is adaptable to other substrates.

[0016] Glazes are generally made from powdered glass combined with colored oxides of such elements as cobalt, chrome, manganese, or nickel. The powder mixture is suspended in water and applied to the ceramic surface by spraying, brushing, dipping, or other known application methods.

[0017] The suspension, or slip, in which the glaze is applied to the ceramic surface must have particular properties to ensure that the glaze is easy to apply, does not run during firing, and adheres well both when wet and after firing. These slip properties are often obtained by adding a small

amount of clay to the suspension and by controlling both the amount of water in the slip as well as the size of the powder particles. Organic surface-active agents (e.g. surfactants, detergents) also can be added to the slip to improve its properties.

5 **[0018]** Colors in glazes are controlled by adding coloring agents to the glassy components of the glaze. Special effects in glazes can also be produced. If salt is added to the kiln during firing, the glaze develops a fine orange-peel texture, which can be uniform or spotty depending upon conditions. A glaze that froths during firing gives a rough surface of broken
10 bubbles known as a blister glaze.

[0019] It was undertaken to develop a baseline glaze composition—that is, a conventional, non-antimicrobial ceramic glaze base—and methodology to aid in identification of suitable and efficacious antimicrobial agents. By way of specific technical background, development of the
15 baseline glaze, its processing, and its maturing temperature are now briefly reviewed.

[0020] Two potential glaze frits were identified that did not contain any of the antimicrobial agents that could comprise at least 95% of the glaze composition. These frits were used to constitute glaze slips that were
20 applied to bisque-fired tile. The slips were evaluated at different solids contents and viscosities. It is also preferable that the glazes be easy to apply by multiple methods.

[0021] A conventional glaze composition used for experimental trials herein is composed of 95% slow-fire base glaze (containing primarily SiO_2 and secondarily, *inter alia*, KNaO , CaO , BaO , SrO Al_2O_3 and B_2O_3).
25

[0022] Alkaline earth oxide materials such as calcium carbonate, wollastonite, and zinc oxide are generally added as raw materials. Other alkaline earth oxides such as lead oxide, strontium oxide, barium oxide, and magnesium oxide are more typically added in a fritted form. The alkaline
30 earth oxides are advantageous because they provide fluxing action without

having a major effect on glaze thermal expansion. Oxides also can serve as coloring compounds.

[0023] Also resident in the glaze composition is 5% EPK kaolin, and an over-addition of 1% Bentonite (an absorbent aluminum silicate clay formed from volcanic ash and well known to those of skill in the ceramic art). This dry material is blended into a sufficient quantity of de-ionized water to produce a glaze slip with a specific gravity of 1.35 ± 0.05 g/cc. This represents a solids content of 41.74%.

[0024] Notable among the many antimicrobial agents used were Ag_2CO_3 (CAS No. 534-16-7); Bi_2O_3 (CAS No. 1304-76-3); CuO (CAS No. 1317-38-0); SnO_2 (CAS No. 18282-10-5); TiO_2 (anatase; CAS No. 13463-67-7); and ZnO (CAS No. 1314-13-2).

[0025] An antimicrobial glazing composition was made by adding together (e.g. by mixing) conventional glazing composition components and antimicrobial agent combinations. The components and antimicrobial agent(s) were added based on weight of the solids content of the baseline glaze, excluding such antimicrobial agent(s). The glaze base is described in greater detail above.

[0026] The glaze base, with antimicrobial agent(s) admixed therein, then was ball milled for fifteen minutes. The milled glaze base was held overnight to allow for hydration, then remixed. The antimicrobial glazing composition then was ready to be applied to a substrate (e.g. a bisque tile).

[0027] All material addition calculations are based upon the percent solids of the baseline glaze and the specific gravity is checked before each group of material evaluation samples is processed. Each material to be evaluated is added to 1000 milliliters of baseline glaze.

[0028] It is expected, however, that other conventional ceramic glaze compositions could be substituted without departing from the essential features of the antimicrobial ceramic glaze as described herein.

[0029] In a third embodiment, a method of affixing a ceramic glaze to a substrate confers durable antimicrobial properties to the substrate. The

method generally comprises providing a ceramic glazing composition having one or more antimicrobial agents disposed therein as set forth in the present disclosure, applying the antimicrobial glazing composition to a substrate, and curing the glazing composition in accordance with conventional glaze-firing techniques.

5 **[0030]** Development work utilized dipping to apply the glaze formulation to tiles, although other methods of application known to those in the art may be used. The glaze is then dried and fixed onto the ceramic surface by firing.

10 **[0031]** During firing, the powdered glass softens and largely equilibrates over the ceramic surface, reacting with the ceramic substrate to form a strong, adherent union therewith. If a glaze is applied to an already fired ceramic substrate, a second firing is necessary to melt and bond the glaze to the substrate. Alternatively, it is possible to apply a glaze to an
15 unfired ceramic and fire both the glaze and substrate together.

[0032] Various components, such as alkali oxide, borates, and lead oxide can be added to the ceramic glaze composition to facilitate softening at lower temperatures in order that the glaze flow more easily during firing and to minimize roughness and defects in the fired ceramic glaze surface.
20 The present antimicrobial combinations are compatible with these common additives.

[0033] The initial stage of a typical ceramic production process is the production of barbotine or slip, a clay from which bathroom ceramic products are made. Barbotine is made from a mixture of clays, kaolin, phyllites,
25 feldspar and quartz.

[0034] Individual pieces are cast by pouring the barbotine into molds made of gypsum or microporous resin. In the casting processes that use gypsum molds, the parts are formed by absorption of water contained in the barbotine through the capillary action of the gypsum. As water leaves the
30 barbotine the part solidifies to a point where the mold can be opened. The still malleable part is then removed from the mold.

5 **[0035]** Casting processes that use resin molds are called "high pressure" processes. Parts are formed by filtering water contained in the barbotine clay through micropores in the resin molds by the application of pressure. The water is eliminated by injecting compressed air along the molds.

10 **[0036]** After casting and removal from the molds, the parts go for drying in kilns under controlled humidity and temperature (approximately 90.degree. C.). The drying cycle lasts about 7 hours, reducing the water content of the part from about 16% to less than 1%. Following this, the parts are inspected to detect possible flaws. The parts then go to the coating process. The coating process is alternatively referred to as the glazing step.

15 **[0037]** The glazing step typically comprises the application of ceramic glaze on the parts using guns in individual booths fitted with exhaust systems and water curtains. Typical ceramic glaze is produced from a mixture of kaolin, feldspar, quartz, colorings and other additives. Once coated, the parts are fired in continuous kilns, reaching temperatures of about 1250°C in an approximately 15-hour cycle. The firing process gives the glazed part the color and transparent appearance that is typical of vitreous china.

20 **[0038]** The procedure to manufacture material evaluation samples is straightforward. A reservoir of baseline glaze, as described above, is maintained. Sample tiles have applied thereon or thereto the present glaze composition; the present disclosure relates to dipped sample tiles.

25 **[0039]** Each dipped tile was placed into a tile sagger, each sagger capable of holding up to twenty tiles. The sagger was placed into one of the two electric kilns and fired to a Pyrometric Cone Equivalent of 06. This measure of thermal history is roughly equivalent to 1889°F. or 1062°C. Baseline glaze samples were fired at temperatures ranging from 1888°F to 2194°F.

30 **[0040]** The above procedure approximates a glaze application in a production environment. The final baseline glaze formulations resulted in

samples having a glassy surface at a low temperature, highly resistant to absorption of dyes, and exhibiting no antimicrobial properties.

5 **[0041]** Microscopic imaging of the baseline glaze/tile interface revealed complete vitrification of the glaze with no inclusions of bubbles or unmelted materials. The baseline samples are the foundation for comparing and judging the candidate materials. The adopted baseline glaze is simple in composition, easy to process and apply, and has a low firing temperature. These attributes greatly facilitated the evaluation of candidate material samples.

10 **[0042]** In production, this dried glaze layer is about 2 millimeters in thickness. A more cost efficient method of producing an antimicrobial surface would entail use of a much thinner secondary glaze applied over the regular (first) glaze. This glaze thickness could be 0.5 millimeters or less in thickness.

15 **[0043]** It is expected that exposure of the glazed tile to microbes will result in microbial contact only with the glazed composition on the surface of the glazed tile. Material below the surface is trapped within the glass of the glaze and thereby sequestered from microbes.

20 **[0044]** A variety of antimicrobial agents were tested in the baseline glaze composition after glazing of a substrate sample. Of these compounds, a variety of combinations also were assessed, as detailed in the following discussion and examples

25 **[0045]** In a fourth embodiment, a ceramic article bearing the above-described antimicrobial glaze composition exhibits durable antimicrobial properties. The antimicrobial ceramic article comprises a substrate, for example a ceramic substrate, having at least a first surface; and a fired or cured glaze disposed on at least a portion of the first surface. The ceramic glazing composition utilized in this embodiment is the same as that described in the first embodiment.

30 **[0046]** Antimicrobial agents were used to manufacture a range of antimicrobial glaze compositions, each composition consisting of one, two or

three antimicrobial agents. Several ceramic articles then were prepared to test the antimicrobial characteristics of the recited glazes. The test articles comprised an underlying ceramic substrate made from a standard commercial barbotine.

5 **[0047]** The glaze used in the testing was the baseline glaze described previously, to which was added varying quantities of antimicrobial agent combinations as noted. The glaze composition was applied to the articles by dipping, and the test articles were then fired.

10 **[0048]** As mentioned, combinations of two antimicrobial agents were assessed for antimicrobial efficacy in fired glazes on ceramic substrates. The compounds Ag_2CO_3 , Bi_2O_3 , CuO , SnO_2 , TiO_2 , and ZnO were evaluated. Each compound was sequentially trialed at 2% in tandem with one of the other five compounds. The second compound was trialed at either 2% or 4%. As an example using Ag_2CO_3 and ZnO , then, the following possibilities
15 were tested: 2% Ag_2CO_3 and 2% ZnO ; 2% Ag_2CO_3 and 4% ZnO ; and 4% Ag_2CO_3 and 2% ZnO .

20 **[0049]** Continuing with this exemplary combination of antimicrobial agents, the combination of 4% Ag_2CO_3 and 4% ZnO was not tested, as 4%/4% combinations generally are considered too expensive to be commercialized and/or are have been observed to negatively affect the aesthetics of the glaze finish. It is expected that such combinations would show efficacy if the 2%/4% and/or 4%/2% combination was efficacious, although antagonistic effects have been observed for some combinations.

25 **[0050]** Test articles also were prepared without any antimicrobial agents in the glaze for use as a negative control.

30 **[0051]** The measure of antimicrobial efficacy is the reduction in the number of organisms surviving the testing protocol in comparison with the baseline standard. Minimum efficacy is assumed to originate at a reduction level of 1 common logarithm ($\log(\text{NOS Std}/\text{NOS Sample})$).

30 **[0052]** Three samples of each addition level and three baseline glaze samples were then tested in triplicate. The testing is in accordance with a

modified JIS Z2801:2000 test protocol (available from Japanese Industrial Standards Committee, Tokyo, Japan). The Z2801 protocol is an internationally known standard test for antimicrobial activity and efficacy. The protocol and specific modifications made thereto are summarized below.

5 **[0053]** Sample tile pieces having a diameter of approximately 55 mm were used. Ceramic glaze composition was applied and fired according to the instructions for the commercial glaze base employed. This preparation process yielded test disks having about a top surface area of about 2500 square millimeters.

10 **[0054]** The comparison test for antimicrobial efficacy used *Klebsiella pneumoniae*, ATCC 4352. The test organism was grown, and a portion of an exponentially growing culture was collected into Japanese Nutrient Broth (JNB) diluted 1/500. An inoculum was prepared at about 10^6 colony-forming units (CFU) per milliliter by dilution with 1/500 JNB.

15 **[0055]** A sample tile was placed on moistened laboratory tissue in a culture plate, and 75 microliters of test inoculum ($\sim 0.8 \times 10^5$ CFU) was pipetted onto the sample surface. A cover slip or film was placed over and in contact with the inoculum to ensure uniform and substantially complete coverage of the inoculum over the sample surface. The culture plate then
20 was incubated for 24 hours at 37° with humidity.

[0056] Bacteria on the sample and cover slip/film were recovered, collected into D/E Neutralizing Broth, and counted. The antimicrobial activity of the test samples is expressed herein as a log reduction value, as compared to the bacterial growth of the corresponding untreated (control)
25 sample. A log reduction is expressed as $\log(U/B)$, where U is the average CFU of the test organism from the inoculum recovered in the Neutralizing Broth from the negative control (untreated) sample tile, and B is the average CFU of the test organism recovered in the Neutralizing Broth from the inoculated sample.

[0057] EXAMPLE 1

[0058] In a first example, 2% Ag_2CO_3 was utilized as a first antimicrobial agent in a family of glaze compositions, which further contained a second antimicrobial agent: one of Bi_2O_3 , CuO , SnO_2 , TiO_2 or ZnO . The second antimicrobial agent was tested at both 2% and 4%. Sample tiles were glazed and the tiles were evaluated according to the above-described modified JIS Z2801:2000 test protocol for the effect of the glazed tile on bacterial reduction. Results are shown in TABLE 1.

[0059] EXAMPLE 2

[0060] In a second example, 2% Bi_2O_3 was utilized as a first antimicrobial agent in a family of glaze compositions, which further contained a second antimicrobial agent: one of Ag_2CO_3 , CuO , SnO_2 , TiO_2 or ZnO . The second antimicrobial agent was tested at both 2% and 4%. Sample tiles were glazed and the tiles were evaluated according to the above-described modified JIS Z2801:2000 test protocol for the effect of the glazed tile on bacterial reduction. Results are shown in TABLE 2.

TABLE 1						<i>K. Pneumoniae</i>
Antimicrobial Combination: Ag_2CO_3						<u>Log reduction</u>
<u>Ag_2CO_3</u>	<u>Bi_2O_3</u>	<u>CuO</u>	<u>SnO_2</u>	<u>TiO_2</u>	<u>ZnO</u>	
--	--	--	--	--	--	NA
2%	--	--	--	--	--	2.4
2%	2%	--	--	--	--	3.6
2%	4%	--	--	--	--	3.0
2%	--	2%	--	--	--	3.9
2%	--	4%	--	--	--	3.8
2%	--	--	2%	--	--	3.2
2%	--	--	4%	--	--	1.9
2%	--	--	--	2%	--	2.4
2%	--	--	--	4%	--	2.7
2%	--	--	--	--	2%	3.0
2%	--	--	--	--	4%	3.3

[0061] EXAMPLE 3

[0062] In a third example, 2% CuO was utilized as a first antimicrobial agent in a family of glaze compositions, which further contained a second antimicrobial agent: one of Ag_2CO_3 , Bi_2O_3 , SnO_2 , TiO_2 or ZnO . The second

antimicrobial agent was tested at both 2% and 4%. Sample tiles were glazed and the tiles were evaluated according to the above-described modified JIS Z2801:2000 test protocol for the effect of the glazed tile on bacterial reduction. Results are shown in TABLE 3.

5

TABLE 2						<i>K. Pneumoniae</i> <u>Log reduction</u>
<u>Antimicrobial Combination: Bi₂O₃</u>						
<u>Bi₂O₃</u>	<u>Ag₂CO₃</u>	<u>CuO</u>	<u>SnO₂</u>	<u>TiO₂</u>	<u>ZnO</u>	
--	--	--	--	--	--	NA
2%	--	--	--	--	--	0.8
2%	2%	--	--	--	--	1.3
2%	4%	--	--	--	--	3.7
2%	--	2%	--	--	--	1.9
2%	--	4%	--	--	--	3.1
2%	--	--	2%	--	--	0.5
2%	--	--	4%	--	--	0.9
2%	--	--	--	2%	--	-0.2
2%	--	--	--	4%	--	0.8
2%	--	--	--	--	2%	0.7
2%	--	--	--	--	4%	1.4

TABLE 3						<i>K. Pneumoniae</i>
Antimicrobial Combination: CuO						
CuO	Ag ₂ CO ₃	Bi ₂ O ₃	SnO ₂	TiO ₂	ZnO	Log reduction
--	--	--	--	--	--	NA
2%	--	--	--	--	--	0.4
2%	2%	--	--	--	--	3.8
2%	4%	--	--	--	--	4.0
2%	--	2%	--	--	--	2.5
2%	--	4%	--	--	--	1.9
2%	--	--	2%	--	--	0.3
2%	--	--	4%	--	--	2.4
2%	--	--	--	2%	--	2.0
2%	--	--	--	4%	--	2.3
2%	--	--	--	--	2%	0.5
2%	--	--	--	--	4%	3.0

10

[0063] EXAMPLE 4

[0064] In a fourth example, 2% SnO_2 was utilized as a first antimicrobial agent in a family of glaze compositions, which further contained a second antimicrobial agent: one of Ag_2CO_3 , Bi_2O_3 , CuO , TiO_2 or ZnO . The second antimicrobial agent was tested at both 2% and 4%. Sample tiles

15

were glazed and the tiles were evaluated according to the above-described modified JIS Z2801:2000 test protocol for the effect of the glazed tile on bacterial reduction. Results are shown in TABLE 4.

5

TABLE 4						<i>K. Pneumoniae</i>
Antimicrobial Combination: SnO ₂						
<u>SnO₂</u>	<u>Ag₂CO₃</u>	<u>Bi₂O₃</u>	<u>CuO</u>	<u>TiO₂</u>	<u>ZnO</u>	<u>Log reduction</u>
--	--	--	--	--	--	NA
2%	--	--	--	--	--	0.1
2%	2%	--	--	--	--	0.5
2%	4%	--	--	--	--	3.7
2%	--	2%	--	--	--	1.2
2%	--	4%	--	--	--	0.5
2%	--	--	2%	--	--	0.5
2%	--	--	4%	--	--	4.0
2%	--	--	--	2%	--	0.0
2%	--	--	--	4%	--	0.1
2%	--	--	--	--	2%	0.2
2%	--	--	--	--	4%	0.4

TABLE 5						<i>K. Pneumoniae</i>
Antimicrobial Combination: TiO_2						
TiO_2	Ag_2CO_3	Bi_2O_3	CuO	SnO_2	ZnO	Log reduction
--	--	--	--	--	--	NA
2%	--	--	--	--	--	0.0
2%	2%	--	--	--	--	0.8
2%	4%	--	--	--	--	3.6
2%	--	2%	--	--	--	0.7
2%	--	4%	--	--	--	0.7
2%	--	--	2%	--	--	0.4
2%	--	--	4%	--	--	3.9
2%	--	--	--	2%	--	0.0
2%	--	--	--	4%	--	0.5
2%	--	--	--	--	2%	0.0
2%	--	--	--	--	4%	0.2

10 [0065] EXAMPLE 5

[0066] In a fifth example, 2% TiO₂ was utilized as a first antimicrobial agent in a family of glaze compositions, which further contained a second antimicrobial agent: one of Ag₂CO₃, Bi₂O₃, CuO, SnO₂ or ZnO. The second antimicrobial agent was tested at both 2% and 4%. Sample tiles were

15 glazed and the tiles were evaluated according to the above-described

modified JIS Z2801:2000 test protocol for the effect of the glazed tile on bacterial reduction. Results are shown in TABLE 5.

[0067] EXAMPLE 6

[0068] In a sixth example, 2% ZnO was utilized as a first antimicrobial agent in a family of glaze compositions, which further contained a second antimicrobial agent: one of Ag₂CO₃, Bi₂O₃, CuO, SnO₂ or TiO₂. The second antimicrobial agent was tested at both 2% and 4%. Sample tiles were glazed and the tiles were evaluated according to the above-described modified JIS Z2801:2000 test protocol for the effect of the glazed tile on bacterial reduction. Results are shown in TABLE 6.

TABLE 6						<i>K. Pneumoniae</i>
Antimicrobial Combination: ZnO						Log Reduction
ZnO	Ag ₂ CO ₃	Bi ₂ O ₃	CuO	SnO ₂	TiO ₂	
--	--	--	--	--	--	NA
2%	--	--	--	--	--	0.4
2%	2%	--	--	--	--	2.4
2%	4%	--	--	--	--	3.7
2%	--	2%	--	--	--	1.3
2%	--	4%	--	--	--	1.5
2%	--	--	2%	--	--	0.5
2%	--	--	4%	--	--	3.7
2%	--	--	--	2%	--	0.2
2%	--	--	--	4%	--	0.2
2%	--	--	--	--	2%	-0.1
2%	--	--	--	--	4%	0.1

[0069] RESULTS

[0070] When two chemical antimicrobial agents are used in combination, either in a single composition or as two separate additions at the point of use, three results are possible: 1) an additive (neutral) effect; 2) an antagonistic effect; or 3) a synergistic effect.

[0071] An additive (neutral) effect has no economic advantage over the individual antimicrobial agents. An antagonistic effect would produce a negative or reduced-efficacy result.

[0072] Only synergism, which is much less likely than an additive or an antagonistic effect, gives a positive result and, therefore possesses economic advantages.

[0073] According to the invention, the combinations identified below
5 demonstrate an unexpected and synergistic antimicrobial effect in a fired ceramic glaze. The combinations of first and second antimicrobial agents, as described herein, achieve superior antimicrobial activity at lower antimicrobial agent concentrations as compared to the antimicrobial capability of either antimicrobial agent alone. Such a superior effect
10 presents a distinct economic advantage and increases the effectiveness of the antimicrobial combination per unit weight.

[0074] Looking at the results for antimicrobial agents singly and in combinations where the first antimicrobial agent is 2% Ag_2CO_3 (results in TABLE 7), it can be seen that a 2% addition of one antimicrobial agent alone
15 demonstrated a range of efficacy results: Ag_2CO_3 (2.4; efficacy), Bi_2O_3 (0.8; weak efficacy), CuO (0.4; very weak efficacy), ZnO (0.4; very weak efficacy), SnO_2 (0.1; essentially no efficacy) and TiO_2 (0.0; no efficacy).

[0075] However, it readily can be seen that simple additions of a second antimicrobial agent at 2% resulted in any one of additive,
20 antagonistic, or synergistic effect. Moreover, addition of the second antimicrobial agent at 4% did not generate results in keeping with expectations based on the test results of individual antimicrobial agents or [2% + 2%] antimicrobial agent combinations.

[0076] For combinations of Ag_2CO_3 and Bi_2O_3 , the [2% Ag_2CO_3 + 2%
25 Bi_2O_3] combination exhibits a synergistic effect relative to the results to be expected.

[0077] However, it is noted that twice the level of the second antimicrobial agent (that is, [2% Ag_2CO_3 + 4% Bi_2O_3]) displays an antagonistic effect, wherein the observed efficacy is lower than both (a) the
30 expected additive log reduction value for [2% Ag_2CO_3 + 4% Bi_2O_3]; and (b)

the observed log reduction value for the [2% Ag₂CO₃ + 2% Bi₂O₃] combination.

TABLE 7						<i>K. Pneumoniae</i> Log reduction
Antimicrobial Combination: Ag ₂ CO ₃						
Ag ₂ CO ₃	Bi ₂ O ₃	CuO	SnO ₂	TiO ₂	ZnO	
--	--	--	--	--	--	NA
2%	--	--	--	--	--	2.4
--	2%	--	--	--	--	0.8
2%	2%	--	--	--	--	3.6
2%	4%	--	--	--	--	3.0
2%	--	--	--	--	--	2.4
--	--	2%	--	--	--	0.4
2%	--	2%	--	--	--	3.9
2%	--	4%	--	--	--	3.8
2%	--	--	--	--	--	2.4
--	--	--	2%	--	--	0.1
2%	--	--	2%	--	--	3.2
2%	--	--	4%	--	--	1.9
2%	--	--	--	--	--	2.4
--	--	--	--	2%	--	0.0
2%	--	--	--	2%	--	2.4
2%	--	--	--	4%	--	2.7
2%	--	--	--	--	--	2.4
--	--	--	--	--	2%	0.4
2%	--	--	--	--	2%	3.0
2%	--	--	--	--	4%	3.3

5

[0078] For combinations of Ag₂CO₃ and CuO, the [2% Ag₂CO₃ + 2% CuO] combination exhibits a strong synergistic effect relative to the expected results based on merely additive principles. Increasing the level of the second antimicrobial agents two-fold (that is, [2% Ag₂CO₃ + 4% CuO]) destroys the synergistic effect, instead resulting in antagonism: the observed efficacy of the [2% Ag₂CO₃ + 4% CuO] combination (3.8) is essentially the same as the [2% Ag₂CO₃ + 2% CuO] combination (3.9/3.8) and well below the very high expected log reduction for this combination.

10

[0079] Ag_2CO_3 and SnO_2 demonstrated surprising and strong synergy for the [2% Ag_2CO_3 + 2% SnO_2] combination (3.2 log reduction).

Unexpectedly, the combination of Ag_2CO_3 and SnO_2 showed marked antagonism when the SnO_2 concentration was doubled to 4%: log reduction
5 tumbled to 1.9, well below both the observed result of 3.2 for the [2% Ag_2CO_3 + 2% SnO_2] combination as well as the expected additive result.

[0080] The results for 2% Ag_2CO_3 and 2% TiO_2 were concluded to be merely additive. Unexpectedly, though, doubling the TiO_2 to 4% resulted in a minor synergistic effect: the efficacy of the [2% Ag_2CO_3 + 4% TiO_2]
10 combination (2.7 log reduction value) was slightly above both the expected additive-effect value for the combination and the observed log reduction for the [2% Ag_2CO_3 + 2% TiO_2] combination.

[0081] The assessment of Ag_2CO_3 + ZnO combinations showed marginal synergy for the [2% Ag_2CO_3 + 4% ZnO] combination (3.0 observed
15 log reduction value). The synergy was lessened with the increase in the ZnO concentration to 4% (3.3 actual).

[0082] The data presented for the other two-compound antimicrobial combinations likewise can be analyzed, and further examples identified of additive, synergistic, and antagonistic effect.

20 **[0083]** A number of combinations were deemed to be of special interest. These combinations are listed in TABLE 8 as showing synergistic effects. That is, the observed log reduction values of the combinations exceeded by a statistically significant margin the expected log reduction values based on the performance of the individual antimicrobial agent
25 components of each combination.

[0084] In addition to the above binary combinations, a less expansive set of tertiary combinations were evaluated. These combinations comprise Bi_2O_3 , ZnO and Ag_2CO_3 . Concentrations of the individual compounds in the tertiary combinations trialed include Bi_2O_3 at 1% and 2%; at ZnO at 1% and
30 2%; and Ag_2CO_3 at 0.5%, 1% and 2%.

TABLE 8
Antimicrobial Combination

<u>Ag₂CO₃</u>	<u>Bi₂O₃</u>	<u>CuO</u>	<u>SnO₂</u>	<u>TiO₂</u>	<u>ZnO</u>	<u>Log Reduction</u>
2%	--	2%	--	--	--	3.9
2%	--	--	2%	--	--	3.2
2%	--	--	--	--	2%	3.0
2%	--	--	--	--	4%	3.3
4%	--	2%	--	--	--	4.0
4%	--	--	2%	--	--	3.7
4%	--	--	--	2%	--	3.6
4%	--	--	--	--	2%	3.7
--	2%	2%	--	--	--	1.9
--	2%	2%	--	--	--	2.5
--	2%	4%	--	--	--	3.1
--	--	2%	4%	--	--	2.4
--	--	2%	--	2%	--	2.0
--	--	2%	--	4%	--	2.3
--	--	2%	--	--	4%	3.0
--	--	4%	2%	--	--	4.0
--	--	4%	--	2%	--	3.9
--	--	4%	--	--	2%	3.7
2%	2%	--	--	--	--	3.6
2%	4%	--	--	--	--	3.0
2%	--	4%	--	--	--	3.8
4%	2%	--	--	--	--	3.7

- [0085]** Initially, the three compounds were employed at equal concentrations of 1% and 2%. As well, combinations were assessed
- 5 wherein one of Bi₂O₃, Ag₂CO₃ and ZnO was added at 2%, while the other two compounds were added at 1%. Lastly, trials were undertaken in which two compounds were added at 2% and the remaining compound at 1%. Results are collected into TABLE 9, with log reduction again expressed against bacterial growth on the untreated sample.
- 10 **[0086]** The tertiary combination data show that the three components were efficacious when present in the ceramic glaze composition at equal concentrations of 1%. Tertiary antimicrobial agent combinations in which an increase to 2% of one or both of the Bi₂O₃ concentration and the ZnO concentration likewise demonstrated efficacy against the bacterial inoculum.
- 15 **[0087]** Antimicrobial activity was greatest for the tertiary combination containing 2% each of Bi₂O₃, Ag₂CO₃ and ZnO. The strength of the

antimicrobial activity for this combination exceeds that expected based on the performance of the component antimicrobial agents individually.

[0088] It should be noted that expectations of activity of binary and tertiary combinations are not reached by simply summing the log reduction values for the separate compounds at the relevant concentrations. Such an approach may be accurate in cases where the various component compounds share a common mechanism of action against the test organism.

10

TABLE 9			<u>Log Reduction</u>
<u>Antimicrobial Agent</u>			
<u>Bi₂O₃</u>	<u>ZnO</u>	<u>Ag₂CO₃</u>	
--	--	--	NA
2%	--	--	0.8
--	2%	--	0.4
--	--	2%	2.4
2%	2%	--	0.7
2%	--	2%	1.3
2%	--	4%	3.7
--	2%	2%	3.0
--	2%	4%	3.7
1%	1%	1%	2.9
2%	1%	1%	2.4
1%	2%	1%	2.3
1%	1%	2%	--
2%	2%	1%	1.8
2%	1%	2%	--
1%	2%	2%	--
2%	2%	2%	3.5

[0089] However, the literature suggests that bismuth, zinc and silver do not behave identically in their mechanisms of bacterial attack. Without wishing to be bound by theory, in the present instance, zinc is believed to exert its effect by disruption of bacterial respiration and the delicate equilibrium of metals in the bacterial cell; bismuth is described as inhibiting the bacteria's ability to take up iron; and silver is believed to act on bacterial proteins involved in nucleic acid replication.

15

[0090] The results demonstrate that the ceramic glaze disclosed herein showed commercially acceptable efficacy against *Klebsiella pneumoniae* relative to the control. These results are exciting as permitting use of materials in considerably lower amounts than heretofore have been employed, especially for those compounds which have previously been explored as antimicrobial agents.

[0091] The observed results further indicate synergistic actions between materials, providing enhanced efficacy levels at lower addition amounts of the antimicrobial agents. Decreased addition amounts reduce the cost and potential deleterious effect of the compounds in the ceramic glaze.

[0092] As well, additional benefits are realized to the environment, in terms of both waste production during manufacture and disposal of the ceramic glaze articles upon termination of their useful product lives.

[0093] As noted previously, the antimicrobial ceramic glaze was designed to impart durable (persistent) and built-in antimicrobial protection to a variety of ceramic articles. Accordingly, the scope of the disclosure includes ceramic articles that incorporate the present antimicrobial glazing. Such articles include, but are not limited to, toilets, bidets, washbasins, towel rails, soap holders, toilet roll holders, water control fixtures (e.g., hot and cold water handles), and ceramic glazed tiles.

[0094] It will therefore be readily understood by those persons skilled in the art that the present composition and methods are susceptible of broad utility and application. Many embodiments and adaptations other than those herein described, as well as many variations, modifications and equivalent arrangements, will be apparent from or reasonably suggested to one of ordinary skill by the present disclosure and the foregoing description thereof, without departing from the substance or scope thereof.

[0095] Accordingly, while the present composition and methods have been described herein in detail in relation to its preferred embodiment, it is to

be understood that this disclosure is only illustrative and exemplary and is made merely for purposes of providing a full and enabling disclosure.

[0096] The foregoing disclosure is not intended or to be construed to limit or otherwise to exclude any such other embodiments, adaptations,
5 variations, modifications and equivalent arrangements.

CLAIMS

What is claimed is:

1. An antimicrobial ceramic glazing composition, comprising:
5 a ceramic glaze base; and
an antimicrobial composition including:
a first antimicrobial agent consisting of Ag_2CO_3 ; and
a second antimicrobial agent that is one of Bi_2O_3 , CuO , SnO_2 ,
 TiO_2 or ZnO ;
10 wherein the first antimicrobial agent is present in the glaze
composition at a concentration of about two to about four percent, by weight
of glaze composition; and
wherein the second antimicrobial agent is present in the glaze
composition at a concentration of from about two percent to about four
15 percent, by weight of glaze composition.
2. The antimicrobial ceramic glazing composition of claim 1
wherein the second antimicrobial agent is Bi_2O_3 .
- 20 3. The antimicrobial ceramic glazing composition of claim 1
wherein the second antimicrobial agent is ZnO .
4. The antimicrobial ceramic glazing composition of claim 1
wherein the first antimicrobial agent and the second antimicrobial agent are
25 present in the glaze composition at substantially equal concentrations.
5. The antimicrobial ceramic glazing composition of claim 1
wherein the concentration of the first antimicrobial agent in the glaze
composition is about two percent;
30 wherein the second antimicrobial agent is one of Bi_2O_3 , CuO , SnO_2 or
 ZnO .

6. The antimicrobial ceramic glazing composition of claim 1 wherein the concentration of the first antimicrobial agent in the glaze composition is about four percent; and
- 5 wherein the second antimicrobial agent is present in the glaze composition at a concentration of about two percent.
7. An antimicrobial ceramic glazing composition, comprising:
a ceramic glaze base; and
- 10 an antimicrobial composition including:
a first antimicrobial agent consisting of Bi_2O_3 , and
a second antimicrobial agent consisting of ZnO ;
wherein the first antimicrobial agent has a concentration in the ceramic glaze composition of from about two percent to about four percent;
- 15 and
wherein the second antimicrobial agent has a concentration of from about two percent to about four percent.
8. An antimicrobial ceramic glazing composition, comprising:
a ceramic glaze base; and
- 20 a synergistic antimicrobial composition including a first antimicrobial agent and a second antimicrobial agent, the antimicrobial composition being one of:
- 25 2% Ag_2CO_3 + 2% Bi_2O_3 ,
2% Ag_2CO_3 + 2% CuO ,
2% Ag_2CO_3 + 4% SnO_2 ,
2% Ag_2CO_3 + 2% ZnO ,
2% Ag_2CO_3 + 4% ZnO ,
2% Bi_2O_3 + 2% CuO ,
30 2% Bi_2O_3 + 4% CuO ,
2% CuO + 4% Ag_2CO_3 ,

- 2% CuO + 4% SnO₂,
 2% CuO + 2% TiO₂,
 2% CuO + 4% TiO₂,
 2% CuO + 4% ZnO,
 5 2% SnO₂ + 4% Ag₂CO₃,
 2% SnO₂ + 4% CuO,
 2% TiO₂ + 4% Ag₂CO₃,
 2% TiO₂ + 4% CuO,
 2% ZnO + 4% Ag₂CO₃, or
 10 2% ZnO + 4% CuO.

9. The antimicrobial ceramic glazing composition of claim 8 wherein the synergistic antimicrobial combination is 2% Ag₂CO₃ + 2% ZnO.

- 15 10. An antimicrobial ceramic glazing composition, comprising:
 a ceramic glaze base; and
 an antimicrobial composition including:
 a first antimicrobial agent consisting of Bi₂O₃; and
 a second antimicrobial agent consisting of ZnO;
 20 wherein the first antimicrobial agent is present in the glaze
 composition at a concentration of about one percent to about four percent,
 by weight of glaze composition; and
 wherein the second antimicrobial agent is present in the glaze
 composition at a concentration of from about one percent to about four
 25 percent, by weight of glaze composition.

11. The antimicrobial ceramic glazing composition of claim 10 wherein:
 the first antimicrobial agent has a concentration in the ceramic glaze
 30 composition of about two percent; and

the second antimicrobial agent has a concentration in the glazing composition of from about two percent to about four percent.

12. The antimicrobial ceramic glazing composition of claim 10,
5 further comprising a third antimicrobial agent consisting of Ag_2CO_3 ;
wherein the first antimicrobial agent has a concentration in the ceramic glaze composition of from about one percent to about two percent;
wherein the second antimicrobial agent has a concentration in the glazing composition of from about one percent to about two percent; and
10 wherein the third antimicrobial agent has a concentration in the ceramic glazing composition of from about one percent to about two percent.

13. The antimicrobial ceramic glazing composition of claim 12 wherein:
15 the first antimicrobial agent, second antimicrobial agent and third antimicrobial agent each has a concentration in the ceramic glaze composition of about one percent.

14. The antimicrobial ceramic glazing composition of claim 12
20 wherein:
the first antimicrobial agent, second antimicrobial agent and third antimicrobial agent each has a concentration in the ceramic glaze composition of about two percent.

15. The antimicrobial ceramic glazing composition of claim 12
25 wherein:
at least one of the first antimicrobial agent and the second antimicrobial agent has a concentration in the ceramic glaze composition of about two percent; and
30 the third antimicrobial agent has a concentration in the ceramic glaze composition of about one percent.

16. A glazed ceramic substrate, comprising:
a ceramic substrate having a first substrate surface; and
a fired ceramic glazing composition disposed on the first substrate
5 surface;
wherein the ceramic glazing composition is the ceramic glazing
composition of one of claims 1 or 7.

17. A glazed ceramic substrate, comprising:
10 a ceramic substrate having a first substrate surface; and
a fired synergistic antimicrobial composition disposed on the first
substrate surface;
wherein the synergistic antimicrobial composition is the ceramic
glazing composition of claim 8.

18. A glazed ceramic substrate, comprising:
a ceramic substrate having a first substrate surface; and
a fired synergistic antimicrobial composition disposed on the first
15 substrate surface;
wherein the synergistic antimicrobial composition is the ceramic
glazing composition of one of claim 10 or 12.

19. A method for manufacturing a glazed ceramic substrate,
comprising:
25 applying an antimicrobial ceramic glazing composition to a ceramic
substrate; and
firing the glazing composition to transform the glazing composition
into a fired state;
wherein the antimicrobial ceramic glazing composition includes an
30 antimicrobial composition as recited in one of claims 1, 7, 10 or 12.

20. A method for manufacturing an antimicrobial ceramic glazing composition, comprising:

providing a ceramic glaze base;

adding to the ceramic glaze base an antimicrobial composition that is

5 one of:

the antimicrobial composition of claim 1,

the antimicrobial composition of claim 7,

the synergistic antimicrobial composition of claim 8,

the antimicrobial composition of claim 10, or

10 the antimicrobial composition of claim 12;

milling the ceramic glaze base and added antimicrobial composition;

rehydrating the milled ceramic glaze base; and

optionally, remixing the rehydrated glaze base.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2008/054190**A. CLASSIFICATION OF SUBJECT MATTER***C04B 35/453(2006.01)i, C04B 35/45(2006.01)i*

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 8 C04B

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Korean Utility models and applications for Utility models since 1975

Japanese Utility models and applications for Utility models since 1975

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

eKIPASS (KIPO internal)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 2006-0048676 A1, (CIBA SPECIALTY CHEMICALS CORPORATION), 09 March 2006 (09.03.2006) see the abstract, claims 1, 7, 8 and 20.	1 - 20
A	US 2005-0252410 A1, (CIBA SPECIALTY CHEMICALS CORPORATION), 17 November 2005 (17.11.2005) see the abstract, claims 1, 5, 11 and 18.	1 - 20
A	US 6368668 B1, (Toto Ltd.), 09 April 2002 (09.04.2002) see the abstract, claims 1, 11 and 17.	1 - 20

☐ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

30 JUNE 2008 (30.06.2008)

Date of mailing of the international search report

30 JUNE 2008 (30.06.2008)

Name and mailing address of the ISA/KR

Korean Intellectual Property Office
Government Complex-Daejeon, 139 Seonsa-ro, Seo-
gu, Daejeon 302-701, Republic of Korea

Facsimile No. 82-42-472-7140

Authorized officer

JOUNG, Meyoung Ju

Telephone No. 82-42-481-8493



INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/US2008/054190

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 2006-0048676 A1	09.03.2006	AU 2004-205733 AA	05.08.2004
		CA 2512892 AA	05.08.2004
		DE 6004005817 C0	24.05.2007
		EP 1585792 A1	19.10.2005
		EP 1585792 B1	11.04.2007
		JP 2006-517988	03.08.2006
		JP 2006-517988 T2	03.08.2006
		KR 10-2005-0103908	01.11.2005
		PA 05007871 A	21.09.2005
		US 7291216	06.11.2007
		US 2005-043233 A1	24.02.2005
		US 2005-043233 AA	24.02.2005
		US 2006-048676 AA	09.03.2006
		US 7291216 BB	06.11.2007
		WO 2004-065492 A1	05.08.2004
US 2005-0252410 A1	17.11.2005	AU 2003-250247 AA	31.12.2003
		AU 2004-205360 A1	05.08.2004
		AU 2004-205360 AA	05.08.2004
		AU 2004-290324 A1	26.05.2005
		AU 2004-290324 AA	26.05.2005
		CA 2489874 AA	24.12.2003
		CA 2511180 AA	05.08.2004
		CA 2511180 A1	05.08.2004
		CA 2543993 AA	26.05.2005
		CA 2543993 A1	26.05.2005
		EP 1682955 A2	26.07.2006
		EP 1517964 A1	30.03.2005
		EP 1585703 A1	19.10.2005
		EP 1682955 A2	26.07.2006
		EP 1682955 A4	04.04.2007
		JP 2005-529835	06.10.2005
		JP 2006-521463	21.09.2006
		JP 2005-529835 T2	06.10.2005
		JP 2005-529835	06.10.2005
		JP 2006-521463 T2	21.09.2006
		KR 10-2005-0021983	07.03.2005
		KR 10-2005-0122197	28.12.2005
		KR 2005122197 A	28.12.2005
		PA 04012887 A	31.03.2005
		PA 05007509 A	21.09.2005
		US 7273522	25.09.2007
		US 2005-096753 A1	05.05.2005
		US 2005-096753 AA	05.05.2005
		US 2005-159823 A1	21.07.2005
		US 2005-159823 AA	21.07.2005

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2008/054190

		US 2005-252410 AA	17.11.2005
		US 2006-257662 AA	16.11.2006
		US 2006-259183 AA	16.11.2006
		US 2006-259184 AA	16.11.2006
		US 7136709 BB	14.11.2006
		US 7155305 BB	26.12.2006
		US 7273522 BB	25.09.2007
		WO 2003-106569 A1	24.12.2003
		WO 2004-065295 A1	05.08.2004
		WO 2005-047996 A2	26.05.2005
		WO 2005-047996 A3	14.07.2005
US 6368668 B1	09.04.2002	AU 1999-49319 A1	21.02.2000
		AU 1999-61250 A1	08.05.2000
		CN 1198886 C	27.04.2005
		CN 1330692	09.01.2002
		CN 1330692 A	09.01.2002
		CN 1330692 T	. .T
		CN 1654133 A	17.08.2005
		CZ 20010378 A3	14.11.2001
		CZ 295546 B6	17.08.2005
		EP 1118385 A1	25.07.2001
		EP 1136527 A1	26.09.2001
		EP 1118385 A1	25.07.2001
		EP 1118385 A4	02.07.2003
		EP 1118385 A1	25.07.2001
		EP 1136527 A1	26.09.2001
		EP 1136527 A4	09.07.2003
		JP 2000-562142	30.07.1999
		JP 3852284 B2	29.11.2006
		WO 00-06300	10.02.2000
		WO 00-23528	27.04.2000
		TW 229617 B	21.03.2005
		TW 229617 A	21.03.2005
		TW 230186 B	01.04.2005
		TW 230186 A	01.04.2005
		US 6368668 BA	09.04.2002
		US 6673433 BA	06.01.2004
		WO 00-06300 A1	10.02.2000
		WO 00-23528 A1	27.04.2000
		WO 2000-06300A 1	10.02.2000
		WO 2000-23528A 1	27.04.2000